Angus Dalgleish | |
---|---|
![]() Angus Dalgleish, March 2016 | |
Born | May 1950 (age 73) [1] Harrow, London, England |
Alma mater | University College London |
Employer | St George's, University of London |
Known for | HIV/AIDS research [2] |
Political party | UK Independence Party (UKIP) |
Website | www |
Angus George Dalgleish (born May 1950) FRCP FRCPath FMedSci [2] is a professor of oncology at St George's, University of London, best known for his contributions to HIV/AIDS research. [3] [4] [5] [6] Dalgleish stood in 2015 for Parliament as a UKIP candidate.
Angus George Dalgleish was born in May 1950 in Harrow, London. [1] [7] [8] Initially educated at the Harrow County School for Boys, [7] Dalgleish received a Bachelor of Medicine, Bachelor of Surgery degree from University College London with an intercalated bachelor's degree in Anatomy. [7]
After various positions in the United Kingdom, Dalgleish joined the Royal Flying Doctor Service in Mount Isa, Queensland, then progressed through positions at various hospitals in Brisbane, Australia, before moving to the Ludwig Institute for Cancer Research in Sydney. [7] [8]
After completion of his training, Dalgleish returned to work in the UK in 1984 at the Institute of Cancer Research. [7] [8] He is a co-discoverer of the CD4 receptor as the major cellular receptor for HIV. [9] [10] [11] [12] In 1986, he was appointed to a consulting position at Northwick Park Hospital, in 1991 he was made Foundation Professor of Oncology at St George's, University of London, [7] and in 1994 he was appointed Visiting Professor at the Institute of Cancer Research in London. [13]
In 1997, he founded Onyvax Ltd., [1] a privately-funded biotechnology company developing cancer vaccines, where he held the position as Research Director; [14] it was dissolved in 2013. [15] Dalgleish is a member of the medical board in Bionor Pharma.[ citation needed ] Dalgleish is on the scientific advisory board of Immodulon, and has stock options in Immunor AS, a disclosure he made in order to have his research work published. [16] [ non-primary source needed ]
During the COVID-19 pandemic, Dalgleish was a proponent of the lab leak theory. [17]
Dalgleish was a member of the UK Independence Party and stood as a candidate in Sutton & Cheam, [18] [19] during the 2015 United Kingdom general election finishing fourth with 10.7% of the vote. [20] Dalgleish campaigned for Leave.EU [21] and appeared on the BBC Radio 4 Today programme presenting the case for Brexit. [22] [18] [23] [24] He was an advocate of Leave Means Leave, a Eurosceptic group. [25]
Dalgleish was elected a Fellow of the Academy of Medical Sciences in 2001 [2] and is also a Fellow of the Royal College of Physicians [ when? ] the Royal College of Pathologists [ when? ] and a Fellow of the Royal Australasian College of Physicians.[ when? ] [23] His citation on election to FMedSci reads:
Professor Angus Dalgleish is Professor of Oncology at St Georges Hospital Medical School London. He has made seminal observations relating to the virology of HIV. In particular he identified CD4 as a major receptive for HIV in humans, produced the first report of a link between Slim Disease in Africa and HIV infection. He also identified the close correlation between the immune response and the presence of tropical spastic paraparesis in patients infected with the HTLV-1 virus. [2]
In October 2023, following a joint investigation analysing emails leaked in 2022 by Russian hacking group working for the Russian FSB, an article was published by Computer Weekly [26] and Byline Times [27] containing several controversial claims about Angus Dalgleish.
According to Semantic Scholar, Dalgleish has 495 publications, 21,234 citations, and 541 "highly influential citations". [30]
in Special Issue Cancer Immunotherapy and Vaccines Research
An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.
Adenoviruses are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Their name derives from their initial isolation from human adenoids in 1953.
Margaret Anne Stanley, OBE FMedSc, is a British virologist and epithelial biologist. She attended the Universities of London, Bristol, and Adelaide. As of 2018, she is an Emeritus Professor of Epithelial Biology in the Department of Pathology at the University of Cambridge and a Fellow of the Academy of Medical Sciences. She is also an Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists and an honorary fellow of Christ's College, Cambridge. Stanley is a research scientist in virology focusing on the human papillomavirus (HPV). Her research work has led to new scientific findings on HPV. Additionally, she uses her expertise on HPV to serve on multiple advisory committees and journal editorial boards.
Christopher Edward Rudd, is a Canadian-born immunologist-biochemist. He is currently Professor of Medicine at the Universite de Montreal and Director, Immunology-Oncology at the Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR).
Frances Rosemary Balkwill is an English scientist, Professor of Cancer Biology at Queen Mary University of London, and author of children's books about scientific topics.
Ulrich Rudolph Mahlknecht is an internationally renowned German/Italian physician scientist.
Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Sir Adrian Vivian Sinton Hill, is an Irish vaccinologist, Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.
Gary J. Nabel is an American virologist and immunologist who is President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts. He was the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
The dendritic cell-based cancer vaccine is an innovation in therapeutic strategy for cancer patients.
The Immune Response Corporation (IRC) was a pharmaceutical company that worked in the development immunotherapeutic products. The firm was founded by Jonas Salk and Kevin Kimberlin when Kimberlin, "asked Salk to become lead scientific advisor for a new biotech company specializing in 'anti-idiotypes,' a novel vaccine technology." Salk called the proposal "liberating."
Peter Edward Fecci is an American neurosurgeon, professor and researcher. He is an Associate Professor of Neurosurgery, Pathology and Immunology at Duke University School of Medicine. He also serves as Director of the Duke Center for Brain and Spine Metastasis, Director of the Brain Tumor Immunotherapy Program, Residency Program Director, and Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke.
A therapeutic vaccine is a vaccine which is administered after a disease or infection has already occurred. A therapeutic vaccine works by activating the immune system of a patient to fight an infection. A therapeutic vaccine differs from a prophylactic vaccine in that prophylactic vaccines are administered to individuals as a precautionary measure to avoid the infection or disease while therapeutic vaccines are administered after the individual is already affected by the disease or infection. A therapeutic vaccine fights an existing infection in the body rather than immunizing the body for protection against future diseases and infections. Therapeutic vaccines are mostly used against viral infections. Patients affected with chronic viral infections are administered with therapeutic vaccines, as their immune system is not able to produce enough efficient antibodies.
The UK Coronavirus Cancer Programme or UKCCP is one of the longest running UK pandemic research programmes to safeguard, monitor and protect individuals living with cancer from COVID-19 across the United Kingdom.
Sir Andrew John Pollard is the Ashall Professor of Infection & Immunity at the University of Oxford and a Fellow of St Cross College, Oxford. He is an Honorary Consultant Paediatrician at John Radcliffe Hospital and the Director of the Oxford Vaccine Group. He is the Chief Investigator on the University of Oxford COVID-19 Vaccine trials and has led research on vaccines for many life-threatening infectious diseases including typhoid fever, Neisseria meningitidis, Haemophilus influenzae type b, streptococcus pneumoniae, pertussis, influenza, rabies, and Ebola.
Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
The MRC Weatherall Institute of Molecular Medicine at the University of Oxford is a research institute located at the John Radcliffe Hospital in Oxford. Founded in 1989 by Sir David Weatherall, the institute focuses on furthering our understanding of clinical medicine at a molecular level. It was one of the first institutes of its kind in the world to be dedicated to research in this area.
Sanjeev Krishna,, is a British physician and parasitologist whose research focuses on affordable diagnosis and treatment of diseases such as COVID-19, malaria, Ebola, African trypanosomiasis, leishmaniasis, and colorectal cancer. Krishna is Professor of Medicine and Molecular Parasitology at St George's, University of London and St George's Hospital.
Margaret Ackerman is an American engineer who is a professor at Dartmouth College. Ackerman develops high throughput tools to evaluate the antibody response in disease states. She oversees biological and chemical engineering in the Thayer School of Engineering.
Lindy Durrant is a British immunologist who is Professor of Cancer Immunotherapy at the University of Nottingham and Chief Scientific Officer and Chief Executive Officer of the UK AIM listed biotech company Scancell Ltd. Durrant's work focusses on harnessing the immune system to treat cancer and infectious disease. Across her career Durrant has developed a panel of monoclonal antibodies which recognise tumour associated glycans, pioneered novel antibody engineering technology to enhance the avidity of monoclonal antibodies as well as developed a number of different cancer vaccine platforms to target cancers such as melanoma, triple negative breast cancer, head and neck cancer amongst others.